Hematological Malignancies

Therapeutic issues

• Anthracycline-based chemotherapy as first line treatment for patients affected with primary bone DLBCL • A survival benefit of the addition of the anti-CD20 monoclonal antibody rituximab to CHOP in primary bone DLBCL has not been demonstrated • The survival benefit of adjuvant irradiation after primary R- chemotherapy is a matter of debate • Optimal radiation volumes and doses